DOC

AI MemoPost-earnings T+1

Healthpeak Properties

As of 2026-10-22/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-22 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q3 results are still ahead, not a completed T+1 print • 2026-11-02

Base target: $20 / p=50% prob

Biggest risk

Q2 lab same-store adjusted NOI fell 3.2% despite sequential occupancy improvement; signed letters of intent may not become leases. Interest expense rose to $92.3 million from $75.1 million a year earlier. [#SEC-8K-2026-08-04] https://www.sec.gov/Archives/edgar/data/765880/000162828026052608/ex99106302026.htm [#SEC-10Q-2026-08-05] https://www.sec.gov/Archives/edgar/data/765880/000162828026053373/peak-20260630.htm

Invalidation

Break below $16 or thesis failure.

What would change my mind?

Q2 FFO as Adjusted was $0.46 per share; Healthpeak raised 2026 FFO-as-adjusted guidance from $1.71–$1.75 to $1.73–$1.77. Continued outpatient leasing, lab recovery and disciplined use of monetization proceeds could support a rerating. [#SEC-8K-2026-08-04] https://www.sec.gov/Archives/edgar/data/765880/000162828026052608/ex99106302026.htm

Research note

Recommendation

—

Confidence

medium

As of

2026-10-22

Base target

$20

p=50%

Bull target

$22

p=25%

Bear target

$16

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Asset monetization and balance-sheet follow-through
Q2 FFO as Adjusted was $0.46 per share; Healthpeak raised 2026 FFO-as-adjusted guidance from $1.71–$1.75 to $1.73–$1.77.
Continued outpatient leasing, lab recovery and disciplined use of monetization proceeds could support a rerating.

BearKey bullets

FFO as Adjusted is non-GAAP and does not by itself establish dividend cash coverage.
[#SEC-8K-2026-08-04]
Higher year-over-year interest expense and capital-allocation execution could offset property gains.

WatchKey bullets

Q3 results are still ahead, not a completed T+1 print

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $20 (p=50%)

Target spread vs base: +14% / -21%

Scenario probabilities

Bull Target: $22 (p=25%)Base Target: $20 (p=50%)Bear Target: $16 (p=25%)

Commentary

This is a pre-earnings monitoring view, not a post-print interpretation. The October 21 anchor is $18.48, but no verified earnings-linked price reaction or post-Q3 analyst target/estimate revision is available. Recent packet headlines are mostly repetitive dividend-stock comparisons; social, options, short-interest and employee measures were not supplied, so the zero fields above denote unavailable data, not neutral readings. The positive deterministic prior is tempered by the erroneous trigger date.

As of 2026-10-22 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Asset monetization and balance-sheet follow-through

Scenarios

Bull Target (Scenario probability)

$22 / p=25% prob

Base Target (Scenario probability)

$20 / p=50% prob

Bear Target (Scenario probability)

$16 / p=25% prob

Analysis 2026-10-22 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-02
Q3 results are still ahead, not a completed T+1 print
The queue's October 21 earnings date conflicts with Healthpeak's October 1 announcement: Q3 results are scheduled for November 2 after market close, with a November 3 call. No Q3 surprise, guidance revision, or post-print reaction can yet be assessed. [#IR-2026-10-01] https://ir.healthpeak.com/news/news-details/2026/Healthpeak-Properties-Announces-Dates-of-Third-Quarter-2026-Earnings-Release-Conference-Call-and-Webcast/default.aspx
Prob 95.00% • Move 5.00% • Priced-in 50.00%
EVENT2026-11-03
Outpatient and lab leasing conversion
Q2 outpatient occupancy reached 90.7% and lab occupancy 78.5%. After quarter-end, Healthpeak reported 882,000 square feet of outpatient and 480,000 square feet of lab leases under signed letters of intent; conversion into executed leases and subsequent occupancy/NOI are the measurable tests, not assured revenue. [#SEC-8K-2026-08-04] https://www.sec.gov/Archives/edgar/data/765880/000162828026052608/ex99106302026.htm
Prob 60.00% • Move 4.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Asset monetization and balance-sheet follow-through
2027-02-28
Healthpeak reported $1.75 billion of year-to-date proceeds through August 3, including about $1.025 billion from the Brookfield outpatient joint-venture transaction, and Q2 net debt to adjusted EBITDAre of 4.7x. Future allocation of proceeds, leverage and per-share FFO—not the already completed sale alone—will determine whether value is realized. [#SEC-8K-2026-08-04] https://www.sec.gov/Archives/edgar/data/765880/000162828026052608/ex99106302026.htm
Prob 55% • Move 5% • Priced-in 50%

Risks

FFO as Adjusted is non-GAAP and does not by itself establish dividend cash coverage. [#SEC-8K-2026-08-04]
Higher year-over-year interest expense and capital-allocation execution could offset property gains. [#SEC-10Q-2026-08-05]
Lab same-store adjusted NOI declined 3.2% in Q2, and signed letters of intent are not completed leases. [#SEC-8K-2026-08-04]
The scheduled follow-up is premature: company IR dates Q3 results to November 2, not October 21; Q3 beat/miss, revised guidance and analyst reaction are unavailable.

Peers

Symbol	Summary
HR	Closer outpatient-medical property comparison, but not a full match for Healthpeak's lab and Janus Living exposure. https://investors.healthcarerealty.com/corporate-profile/press-releases/news-details/2026/Healthcare-Realty-Reports-Second-Quarter-2026-Results-and-Further-Increases-Full-Year-2026-Guidance/default.aspx
VTR	Healthcare REIT with outpatient, research and senior-housing assets; its heavier senior-housing emphasis limits direct multiple comparisons. https://ir.ventasreit.com/news/news-details/2026/Ventas-Reports-2026-Second-Quarter-Results/default.aspx
WELL	Healthcare REIT with senior-housing and outpatient exposure, but its portfolio mix and scale differ materially from DOC's. https://welltower.com/investors/press-release-details/?id=808

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-22

Loading AI feed…

Symbol

Summary

Closer outpatient-medical property comparison, but not a full match for Healthpeak's lab and Janus Living exposure. https://investors.healthcarerealty.com/corporate-profile/press-releases/news-details/2026/Healthcare-Realty-Reports-Second-Quarter-2026-Results-and-Further-Increases-Full-Year-2026-Guidance/default.aspx

VTR

Healthcare REIT with outpatient, research and senior-housing assets; its heavier senior-housing emphasis limits direct multiple comparisons. https://ir.ventasreit.com/news/news-details/2026/Ventas-Reports-2026-Second-Quarter-Results/default.aspx

WELL

Healthcare REIT with senior-housing and outpatient exposure, but its portfolio mix and scale differ materially from DOC's. https://welltower.com/investors/press-release-details/?id=808